Compare SHOO & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | HAE |
|---|---|---|
| Founded | 1990 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1996 | 1996 |
| Metric | SHOO | HAE |
|---|---|---|
| Price | $47.23 | $90.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | $42.14 | ★ $84.13 |
| AVG Volume (30 Days) | ★ 1.0M | 738.0K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.38 | 0.72 |
| Revenue | ★ $2,534,109,000.00 | $910,373,000.00 |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | $5.90 | $5.23 |
| P/E Ratio | ★ $34.31 | $125.53 |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $26.05 | $47.32 |
| 52 Week High | $49.70 | $92.25 |
| Indicator | SHOO | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 71.51 |
| Support Level | $42.54 | $79.52 |
| Resistance Level | $49.70 | N/A |
| Average True Range (ATR) | 1.70 | 3.10 |
| MACD | -0.03 | 0.44 |
| Stochastic Oscillator | 63.65 | 91.84 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.